Holen Sie sich die Stockscreener-App
25.35
0.04%
-0.010
Handel nachbörslich:
25.43
0.08
+0.32%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer (PFE) Faces Legal Challenges Over Depo-Provera's Increased Brain Tumor Risk - simplywall.st
Pfizer’s New Phase 1 Study: A Potential Game-Changer? - TipRanks
Pfizer’s Pediatric Pantoprazole Study: A Market Watch - TipRanks
Pfizer Bolsters Oncology Pipeline with $1.25B 3SBio Deal - Contract Pharma
Pfizer faces lawsuits over Depo-Provera cancer risk (PFE:NYSE) - Seeking Alpha
Pfizer’s ‘Depo-Provera’ Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits - GlobeNewswire
Pfizer licenses cancer immunotherapy from 3SBio in $1.25 billion deal - Investing.com
Pfizer Completes Licensing Agreement with 3SBio - Business Wire
Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings - The Globe and Mail
Ex-Dividend Reminder: GE HealthCare Technologies, Pfizer and Old Second Bancorp - Nasdaq
Pfizer Nears Major Bottom: A Turning Point for Investors? - FXEmpire
Pfizer: Building The Next Oncology Empire - Seeking Alpha
Why Regency Centers, Tyson Foods, And Pfizer Are Winners For Passive Income - Yahoo Finance
Here's What To Expect From Pfizer's Non-Oncology Drugs In Q2 Earnings - Barchart.com
Pfizer Stock (PFE) Opinions on Stagnant Performance and Policy Risks - Quiver Quantitative
Is Pfizer Inc. a good long term investmentRecord-setting profit potential - Autocar Professional
What analysts say about Pfizer Inc. stockBreakthrough profits - jammulinksnews.com
Pfizer Inc. (NYSE:PFE) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed? - Yahoo Finance
Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II - insights.citeline.com
Request for Proposals: Pfizer Independent Medical Education Grant Program - fundsforNGOs
Lobbying Update: $3,490,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - AOL.com
What drives Pfizer Inc. stock priceFree Stock Market Return Analysis - Jammu Links News
Pfizer Inc. Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com
Can Pfizer Limited (PFIZER) Maintain Its ValuationFree Market Volatility Navigation Tips - Jammu Links News
Pfizer’s Discounted Stock Offers Yield, But Risks Linger - Finimize
Sally Susman helped steer Pfizer through COVID-19. Her advice for leaders? Learn to write — and listen. - Business Insider
Pfizer Inc. - Britannica
Pfizer’s (PFE) Dividend Safety: Balancing Innovation and Shareholder Returns - Yahoo Finance
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Morgan Stanley Maintains a Hold on Pfizer (PFE) - MSN
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - MSN
Pfizer’s Hemophilia Study: Insights into Treatment Patterns and Outcomes - TipRanks
Pfizer’s BeneFIX Study Update: Key Insights for Investors - TipRanks
Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer in Maternal Health - TipRanks
Pfizer’s Lyme Disease Vaccine Study: Key Insights for Investors - TipRanks
Pfizer’s Rimegepant Study: A New Hope for Migraine Sufferers - TipRanks
Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention? - TipRanks
Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer in Infant RSV Prevention - TipRanks
Pfizer's Global Health Fellows Program: Leveraging Colleagues’ Expertise to Help Improve Healthcare Access Around the World - Pfizer
Pfizer’s Latest Study on PF-07799544: A Potential Game-Changer for Advanced Solid Tumors - TipRanks
Rx Rundown: Sarepta Therapeutics, Juul, Pfizer and more - Medical Marketing and Media
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
13 Cheap Stocks Under $50 to Buy Now - Insider Monkey
Pfizer, Lilly spend big on telehealth contracts: Lawmaker report - Sherwood News
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit - insights.citeline.com
Pfizer Just Reversed Its Bull Run. Is It A Buy Or A Sell? - Investor's Business Daily
0.32%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):